Literature DB >> 8520028

The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function.

D J Rawlings1, O N Witte.   

Abstract

The genetic defect associated with two closely related primary immunodeficiencies was recently identified as a deficiency of function of a new cytoplasmic tyrosine kinase, Bruton's tyrosine kinase (Btk). Btk and related genes expressed primarily in hematopoietic cells (Itk, Tec, Drsrc28C and Txk) comprise a new subfamily of cytoplasmic tyrosine kinases. These proteins share significant structural and sequence homology including an amino-terminal pleckstrin homology (PH) domain not present in other cytoplasmic tyrosine kinase subfamilies. This domain plays an essential role in regulation and function of the Btk subfamily proteins. Genetic evidence supports a critical role for Btk in B-lineage development. Additional studies demonstrate activation of these proteins in multiple hematopoietic signaling pathways including the B cell antigen receptor, several cytokine receptors, and a potential novel role in heterotrimeric G protein associated receptor signaling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520028     DOI: 10.1006/smim.1995.0028

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  30 in total

1.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.

Authors:  S Nisitani; A B Satterthwaite; K Akashi; I L Weissman; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

3.  Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase.

Authors:  Y C Ma; X Y Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 4.  X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.

Authors:  C I Smith; C M Bäckesjö; A Berglöf; L J Brandén; T Islam; P T Mattsson; A J Mohamed; S Müller; B Nore; M Vihinen
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

6.  The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.

Authors:  Nicole Stadler; Astrid Hasibeder; Pamela Aranda Lopez; Daniel Teschner; Alexander Desuki; Oliver Kriege; Alexander N R Weber; Christoph Schulz; Christian Michel; Georg Heβ; Markus P Radsak
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

7.  Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation.

Authors:  Y T Tsai; Y H Su; S S Fang; T N Huang; Y Qiu; Y S Jou; H M Shih; H J Kung; R H Chen
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts.

Authors:  Raji E Joseph; Thomas E Wales; D Bruce Fulton; John R Engen; Amy H Andreotti
Journal:  Structure       Date:  2017-08-31       Impact factor: 5.006

9.  Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.

Authors:  F Cervantes-Gomez; V Kumar Patel; P Bose; M J Keating; V Gandhi
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

10.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.